Literature DB >> 22904131

Arginase-1, HepPar-1, and Glypican-3 are the most effective panel of markers in distinguishing hepatocellular carcinoma from metastatic tumor on fine-needle aspiration specimens.

Dana T Timek1, Jianhui Shi, Haiyan Liu, Fan Lin.   

Abstract

Distinction of liver metastases from hepatocellular carcinoma (HCC) may present a diagnostic challenge. Arginase-1 (Arg-1) is a marker for HCC recently described in some literature. Immunohistochemical evaluation of Arg-1, hepatocyte paraffin-1 (HepPar-1), and glypican-3 expression was performed on 1,240 surgical specimens and 62 liver fine-needle aspiration specimens (29 HCCs, 28 metastatic tumors, and 5 benign liver cases). The staining results on tissue microarray sections showed that 2.7% and 3.1% of nonhepatic tumor cases were positive for HepPar-1 and glypican-3, respectively; none was positive for Arg-1. For fine-needle aspiration specimens, 19 HCCs were positive for all 3 markers; 9 were positive for 1 or 2 markers; and only 1 case was negative for all 3 markers. These data demonstrate that Arg-1 is the most specific marker in differentiating a non-HCC from HCC. It is recommended to use 3 markers as a panel in distinguishing HCC from metastatic carcinoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22904131     DOI: 10.1309/AJCPK1ZC9WNHCCMU

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  36 in total

Review 1.  Tissue diagnosis of hepatocellular carcinoma.

Authors:  Deepali Jain
Journal:  J Clin Exp Hepatol       Date:  2014-04-01

Review 2.  Proteoglycans in liver cancer.

Authors:  Kornélia Baghy; Péter Tátrai; Eszter Regős; Ilona Kovalszky
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

3.  The Applicability of a Human Immunohistochemical Panel to Mouse Models of Hepatocellular Neoplasia.

Authors:  Kenneth J Salleng; Frank L Revetta; Natasha G Deane; M Kay Washington
Journal:  Comp Med       Date:  2015-10       Impact factor: 0.982

4.  Improved method increases sensitivity for circulating hepatocellular carcinoma cells.

Authors:  Hui-Ying Liu; Hai-Hua Qian; Xiao-Feng Zhang; Jun Li; Xia Yang; Bin Sun; Jun-Yong Ma; Lei Chen; Zheng-Feng Yin
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

5.  Glycosaminoglycans and glycolipids as potential biomarkers in lung cancer.

Authors:  Guoyun Li; Lingyun Li; Eun Ji Joo; Ji Woong Son; Young Jin Kim; Jae Ku Kang; Kyung Bok Lee; Fuming Zhang; Robert J Linhardt
Journal:  Glycoconj J       Date:  2017-08-18       Impact factor: 2.916

6.  Branched chain in situ hybridization for albumin as a marker of hepatocellular differentiation: evaluation of manual and automated in situ hybridization platforms.

Authors:  Mohammad Shahid; Aysha Mubeen; Julie Tse; Sanjay Kakar; Adrian C Bateman; Darrell Borger; Miguel N Rivera; David T Ting; Vikram Deshpande
Journal:  Am J Surg Pathol       Date:  2015-01       Impact factor: 6.394

7.  The Diagnostic Value of Arginase-1, FTCD, and MOC-31 Expression in Early Detection of Hepatocellular Carcinoma (HCC) and in Differentiation Between HCC and Metastatic Adenocarcinoma to the Liver.

Authors:  Osama H Labib; Ola A Harb; Osama H Khalil; Taha A Baiomy; Loay M Gertallah; Rham Z Ahmed
Journal:  J Gastrointest Cancer       Date:  2020-03

8.  [Hepatocellular carcinomas and their mimics].

Authors:  H-P Fischer; D Goltz
Journal:  Pathologe       Date:  2019-02       Impact factor: 1.011

9.  Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver.

Authors:  Taiseer R Ibrahim; Samar M Abdel-Raouf
Journal:  Pathol Oncol Res       Date:  2014-08-10       Impact factor: 3.201

10.  Small heterodimer partner overexpression partially protects against liver tumor development in farnesoid X receptor knockout mice.

Authors:  Guodong Li; Bo Kong; Yan Zhu; Le Zhan; Jessica A Williams; Ossama Tawfik; Karen M Kassel; James P Luyendyk; Li Wang; Grace L Guo
Journal:  Toxicol Appl Pharmacol       Date:  2013-06-26       Impact factor: 4.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.